This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.

March 7, 2025 (Investorideas.com Newswire) Investorideas.com, a recognized top 100 investment site for stock news announces ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...

This was the fourth biotech IPO of 2025, and the company raised around $219 million in its IPO, intended to advance its cystic fibrosis treatments. That is a market dominated Vertex ...

As you can see below, the number of biotech IPOs spiked from 43 to 99 from 2019 ... which was before the pandemic. The current hot trend is weight loss/muscle gain drugs due to GLP-1’s success.

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are coming in—and it’s led the biotech to abandon its lead asset.

Paramesu Biotechs IPO aims to raise ₹600 crore for expansion and debt repayment, showcasing strong financial performance and ...

Oncolytics Biotech Inc. (ONCY ... as indicated by its RSI reading of 27.83. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.

Hinge Health, Inc. targets a $326B market with innovative musculoskeletal care solutions. Click here to find out more about the upcoming HNGE stock IPO.